

Cognizant Announces New Shared Investigator Platform Capabilities in Collaboration with TransCelerate BioPharma Inc.

Converged Digital Ecosystem Enhances Life Sciences Companies' Collaboration to Accelerate Development of New Medicines

Platform to be Showcased at DIA 2017 Annual Meeting

TEANECK, N.J., June 16, 2017 /PRNewswire/ -- [Cognizant](#) (NASDAQ: CTSH), as part of its collaboration with [TransCelerate BioPharma Inc.](#), a non-profit organization with membership comprised of global biopharmaceutical companies, today announced new Shared Investigator Platform (SIP) capabilities that make it easier for clinical trial researchers to access, share and analyze data.

SIP is a multi-tenanted, cloud-based, open architecture collaboration platform to support common research and clinical trial requirements for the biopharmaceutical industry. It brings together best of breed technologies from an eco-system of partners to streamline collaboration and provide a centralized point of access for trial sponsors, CROs, investigators, clinical researchers and ultimately regulators. By converging the work of multiple stakeholders, the SIP reduces the risks and complexity of clinical development, and significantly improves efficiency.

Cognizant and TransCelerate BioPharma will be demonstrating the platform's capabilities at DIA 2017, the Drug Information Association's annual meeting, June 18-22 at McCormick Place in Chicago, IL. The event is expected to be attended by 7,000 professionals in the pharmaceutical, biotechnology, and medical device communities from more than 51 countries (Cognizant Booth # 1043). Cognizant and TransCelerate BioPharma will present at the Innovation Theater Showcase on Wednesday, June 21 at 12 noon.

"The Shared Investigator Platform is a critical initiative for TransCelerate and our membership. Since we launched it in 2016, some of our members are already experiencing the benefits of a single platform and we continue to collaborate closely with Cognizant and other partners to deliver enhanced usability and functionality throughout 2017," said, Dalvir Gill, Ph.D., CEO of TransCelerate. "The SIP is a transformative technology that benefits researchers by simplifying processes and reducing time and effort spent on common study activities."

"We are excited about our ongoing collaboration with TransCelerate, its member companies and other partners to enhance this industry first initiative, which focuses on significantly simplifying, streamlining and transforming clinical development through greater stakeholder collaboration and communication. Our focus has been on building a robust, scalable and open architecture platform and to enable continuous innovation by leveraging and incorporating new solutions and technologies from an eco-system of partners. Through this, we are making the whole experience easier for investigators so that they can focus on science and patient care," said Bhaskar Sambasivan, Senior Vice President and Global Head of Life Sciences Markets at Cognizant.

Additional information on the capabilities of the Shared Investigator Platform can be found here:

<https://www.cognizant.com/whitepapers/making-life-easier-for-investigators-a-shared-solution-for-smarter-faster-clinical-trials-codex1385.pdf>

Learn More About Cognizant's Healthcare and Life Sciences Practice

<http://www.cognizant.com/healthcare>

<http://www.cognizant.com/life-sciences>

About Cognizant

Cognizant (NASDAQ-100: CTSH) is one of the world's leading professional services companies, transforming clients' business, operating and technology models for the digital era. Our unique industry-based, consultative approach helps clients envision, build and run more innovative and efficient businesses. Headquartered in the U.S., Cognizant is ranked 205 on the Fortune 500 and is consistently listed among the most admired companies in the world. Learn how Cognizant helps clients lead with digital at www.cognizant.com or follow us @Cognizant.

About TransCelerate BioPharma Inc.

TransCelerate BioPharma Inc. is a non-profit organization dedicated to improving the health of people around the world by accelerating and simplifying the research and development (R&D) of innovative new therapies. The organization's mission is to collaborate across the global biopharmaceutical R&D community to identify, prioritize, design and facilitate implementation of solutions designed to drive the efficient, effective and high quality delivery of new medicines. TransCelerate evolved from discussions at various forums for executive R&D leadership to debate current issues facing the industry and examine solutions for addressing agreed-upon common challenges. The founding member companies are AbbVie, AstraZeneca, Boehringer

Ingelheim, Bristol-Myers Squibb, Eli Lilly and Company, GlaxoSmithKline, Johnson & Johnson, Pfizer, the Roche Group, and Sanofi. Additional members that have joined since the inception of TransCelerate include Allergan, Inc., Amgen, Astellas Pharma Inc., EMD Serono, Inc. (a subsidiary of Merck KGaA, Darmstadt, Germany), Medgenics, Inc., Merck & Co., Inc., Novo Nordisk, Shionogi & Co., Ltd. and UCB.

Membership in TransCelerate is open to pharmaceutical and biotechnology companies with Research & Development operations. Executive offices are located in Philadelphia, Pennsylvania. For more information, please visit <http://www.transceleratebiopharmainc.com>.

SOURCE Cognizant

For further information: U.S.: Rick Lacroix, +1-201-470-8961, rick.lacroix@cognizant.com; Europe: Grazia Valentino-Boschi, +33 (0)6 07 85 80 63, grazia.valentino-boschi@cognizant.com; Asia-Pac: Harsh Kabra, +91-855-188-2111, harsh.kabra@cognizant.com

Additional assets available online:  [Photos \(1\)](#)

<https://news.cognizant.com/2017-06-16-Cognizant-Announces-New-Shared-Investigator-Platform-Capabilities-in-Collaboration-with-TransCelerate-BioPharma-Inc>